EMD Serono is the third manufacturer to partner with the Trump administration on “Most Favored Nation” (MFN) pricing – following earlier agreements with Pfizer and AstraZeneca (AZ). Similar to the Pfizer and AZ agreements, EMD Serono has agreed to offer MFN pricing on all new innovative medications, to repatriate international revenue on existing medications, and to provide Medicaid programs access to MFN drug prices.
EMD Serono will offer direct to consumer (DTC) sales on its IVF therapies, including Gonal-f (follitropin alfa injection), Ovidrel (choriogonadotropin alfa injection), and Cetrotide (cetrorelix acetate for injection) and when all three therapies are used in a typical IVF protocol together, patients will receive an 84% discount off listing price. EMD Serono’s fertility medications will be available on the TrumpRx website as well as through an expanded pharmacy network starting in January 2026. Other EMD Serono medications will also be offered via DTC purchasing with a discount off current listing price, these include multiple sclerosis medications Rebif (interferon Beta-1a) and Mavenclad (cladribine), oncology drugs Tepmetko (tepotinib hydrochloride) and Bavencio (avelumab), and somatropin products Saizen and Serostem.
